Finzati - Logo
IMMP logo

Immutep Limited

IMMP • Biotechnology
$0.36
▼ -0.00 (-0.05%)
Current price
EarningsSep 2, 11:10 AM UTC
New financial eventQ4 2026Positive

Immutep Limited has reported Q4 2026 financial results

The latest report is predominantly positive and shows an overall improvement in financial performance. Revenue and profitability advanced at a meaningful pace, while the weaker areas should be reviewed in context. The report may attract increased investor attention and price volatility.

Finzati signal
Positive development
Sep 2, 11:10 AM UTC
Improved
+460.33%
Revenue
Improved
+10.56%
Net income
Improved
+13.07%
Free cash flow
Changed
-46.89%
Cash
Improved
-73.74%
Total debt
What changed
↑Revenue increased 460.3% versus the comparable prior period, indicating stronger top-line growth.
↑Net income increased 10.6%, showing improved profitability.
↑Free cash flow increased 13.1%, strengthening cash generation.
↓Total debt declined 73.7%, modestly improving financial flexibility.
Based on newly processed financial statements and comparable prior-period data.This is informational analysis, not investment advice.
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Sep 2, 2026, 11:10 AM UTCLast profile update: Sep 4, 2026, 12:14 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.36
Change-0.05%
Market Cap$53.81M
52W Range0.29 - 3.53
Beta2.25
Gross Margin83.01%
Oper. Margin-5.76%
Profit Margin-5.45%
Debt/Eq0.02
Current Ratio5.69
Quick Ratio5.69
Target$4.25

Investment DNA

How strong this company looks for long-term investors

52
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
71/100
Why this score▼
Positive revenue growth · 164.5%Manageable debt level · 0.02Healthy liquidity · 5.69Weak profitability

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-09-04
Low
$3.50
Mean
$4.25
Median
$4.25
High
$5.00

Company Overview

IPO: 4/19/2012
Industry: Biotechnology
P/B i: 1.44
Debt / Equity i: 0.02
Operating Margin: -576.21%
Net Margin: -544.79%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.02
Current Ratio: 5.69
Quick Ratio: 5.69
Status: Good

Insider Transactions

Recent executive and insider activity

Boyce Elisabeth Amanda
Transaction: 12/01/2028
OTHER
Change
+295,985
Price
Not reported
Filing
04/16/2026
Type
OTHER
Boyce Elisabeth Amanda
Transaction: 03/18/2026
OTHER
Change
0
Price
Not reported
Filing
04/16/2026
Type
OTHER
Miller Deanne Diem
Transaction: 12/01/2028
OTHER
Change
+600,000
Price
Not reported
Filing
04/13/2026
Type
OTHER